Biognosys and NeoGenomics Expand Global Strategic Partnership Initiatives on Multiple Discovery Proteomics Solutions Supporting Biopharma R&DBusiness Wire • 04/11/22
NeoGenomics, Inc. Expands Its Global Strategic Partnership Initiatives with Biognosys AG on Multiple Next Generation Proteomics Solutions Supporting Biopharma R&DAccesswire • 04/11/22
NeoGenomics Schedules its First Quarter 2022 Earnings Release for April 27, 2022Accesswire • 04/08/22
NEO INVESTOR NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages NeoGenomics, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - NEOPRNewsWire • 04/04/22
NEOGENOMICS ALERT: Bragar Eagel & Squire, P.C. is Investigating NeoGenomics, Inc. on Behalf of NeoGenomics Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 04/01/22
SHAREHOLDER ALERT: Investigation of NeoGenomics (NEO) Announced by Holzer & Holzer, LLCNewsfile Corp • 03/31/22
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages NeoGenomics, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – NEOBusiness Wire • 03/31/22
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of NeoGenomics, Inc. (NEO) on Behalf of InvestorsBusiness Wire • 03/30/22
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of NeoGenomics, Inc. (NEO) on Behalf of InvestorsBusiness Wire • 03/30/22
The Law Offices of Frank R. Cruz Announces Investigation of NeoGenomics, Inc. (NEO) on Behalf of InvestorsBusiness Wire • 03/29/22
Kirby McInerney LLP Announces an Investigation of Shareholder Claims on Behalf of NeoGenomics, Inc. (NEO) InvestorsBusiness Wire • 03/29/22
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in NeoGenomics, Inc. with Losses of $100,000 to Contact the FirmBusiness Wire • 03/29/22
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in NeoGenomics, Inc. with Losses of $100,000 to Contact the FirmBusiness Wire • 03/29/22
NeoGenomics stock plunges more than 20% as CEO departs after disappointing quarterMarket Watch • 03/28/22
NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay in Non-Small Cell Lung CancerAccesswire • 03/17/22
Inivata and Collaborators Publish Clinical Validation Data for RaDaR™ Assay in Non-Small Cell Lung CancerGlobeNewsWire • 03/17/22
NeoGenomics (NEO) CEO, Mark Mallon on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/23/22
NeoGenomics Reports Full Year Revenue of $484 Million and $126 Million for the Fourth Quarter of 2021Accesswire • 02/23/22
NeoGenomics appoints Dr. Shashi Kulkarni, a World-Renowned Oncology Genomics Expert, and Innovator as Chief Scientific OfficerAccesswire • 02/14/22
Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR™ in Head and Neck Squamous Cell CarcinomaGlobeNewsWire • 02/11/22